Mylatrip (Frovatriptan Succinate Monohydrate)

Frovatriptan selectively stimulates serotonin 5‑HT1B and 5‑HT1D receptors on cranial blood vessels and trigeminal nerve endings. This causes vasoconstriction of dilated intracranial arteries and blocks the release of neuropeptides that drive migraine pain, thereby terminating the attack.

The dose of Mylatrip is determined by the prescribing clinician based on the patient’s medical history, severity of migraine, and response to therapy. The prescriber will provide specific dosing instructions and any necessary limits on the number of doses per month.

The safety of frovatriptan in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mylatrip (frovatriptan) has a longer half‑life than many other triptans, which can provide sustained relief and a lower risk of headache recurrence. Its efficacy is comparable, but individual response varies, so clinicians may choose based on patient tolerance, recurrence rates, and drug‑interaction profile.

Mylatrip tablets should be stored at room temperature, below 25 °C, in the original packaging. Protect them from moisture, excessive heat, and direct sunlight to maintain product stability throughout its shelf life.

Mylatrip is taken orally, usually as a single tablet at the onset of migraine symptoms. If the migraine persists after two hours, a second dose may be considered, but the total number of doses per month should not exceed the limit set by the prescriber.

Serious risks include coronary vasospasm or myocardial infarction, especially in patients with underlying cardiovascular disease, and serotonin syndrome when combined with other serotonergic agents. Patients should be educated to seek immediate medical attention for chest pain, severe hypertension, or signs of serotonin excess.

Mylatrip is contraindicated in patients with uncontrolled coronary artery disease, severe hypertension, a history of myocardial infarction, peripheral vascular disease, or in those who have used ergot derivatives or other triptans within the same 24‑hour period. It should also be avoided in patients with known hypersensitivity to frovatriptan.